Filtros de búsqueda

Lista de obras de

"Adaptive pathways" to drug authorisation: adapting to industry?

artículo científico publicado en 2016

'Linkage' pharmaceutical evergreening in Canada and Australia

artículo científico publicado en 2007

A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada

artículo científico publicado en 2016

A call to mandate patient access to personal primary care medical records across Canada

artículo científico publicado en 2018

A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences

artículo científico publicado en 2006

A compromise too far: a review of Canadian cases of direct-to-consumer advertising regulation

artículo científico publicado en 2014

A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States - 2007 to 2016

artículo científico publicado en 2020

A hypertensive snow bird

artículo científico publicado en 2005

A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents

artículo científico publicado en 2015

A systematic review of studies comparing health outcomes in Canada and the United States

artículo científico publicado en 2007

Adverse drug events: counting is not enough, action is needed

scientific article published on 01 April 2006

Affordable Biologics for All

artículo científico publicado en 2020

An International Mapping of Medical Care in Nursing Homes

Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts

scientific article published on 28 November 2019

Are academia-pharma partnerships essential for novel drug discovery in the time of the COVID-19 pandemic?

scientific article published on 14 December 2020

Are drugs too expensive in Canada? Yes.

artículo científico publicado en 2006

Assessing the quality of drug detailing

artículo científico publicado en 2002

Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study

article

Baclofen and Alcohol Use Disorders: Breakthrough or Great White Elephant?

scientific article published on 01 February 2020

Ban Drug Advertisements ⬇️

artículo científico publicado el 1 de septiembre de 2011

Beyond patents: The GAVI Alliance, AMCs and improving immunization coverage through public sector vaccine production in the global south ⬇️

artículo científico publicado el 1 de marzo de 2011

Bigger and better: how Pfizer redefined erectile dysfunction

artículo científico publicado en 2006

CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs

artículo científico publicado en 2014

CJEM and pharmaceutical advertisements: it's time for an end

artículo científico publicado en 2009

COVID-19: still much to learn

artículo científico publicado en 2020

Can direct-to-consumer advertising of prescription drugs be effectively regulated?

artículo científico publicado en 2019

Canada and access to medicines in developing countries: intellectual property rights first ⬇️

artículo científico publicado el 3 de septiembre de 2013

Canada finally opens up data on new drugs and devices

scientific article published on 17 April 2019

Canada's Access to Medicines Regime: Promise or Failure of Humanitarian Effort? ⬇️

artículo científico publicado el 1 de febrero de 2010

Canada's patented medicine notice of compliance regulations: balancing the scales or tipping them?

artículo científico publicado en 2011

Canadian status of "drugs to avoid" in 2017: a descriptive analysis

article

Clinical trial transparency: many gains but access to evidence for new medicines remains imperfect

artículo científico publicado en 2015

Clinical trials in Canada: whose interests are paramount?

artículo científico publicado en 2008

Clinical trials register

scientific article published on 01 July 2004

Combating corruption in the pharmaceutical arena

artículo científico publicado en 2018

Commercial influence and the content of medical journals

artículo científico publicado en 2006

Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom

scientific article published on 01 July 2019

Complete dissociation from the health care and pharmaceutical industry

artículo científico publicado en 2015

Continuing medical education and pharmaceutical industry involvement: An evaluation of policies adopted by Canadian professional medical associations

artículo científico publicado en 2017

Copayments and the evidence-base paradox

scientific article published on 01 May 2015

Cost recovery by Health Canada and drug safety: a time-series analysis

article

Coverage with evidence development for pharmaceuticals: a policy in evolution?

artículo científico publicado en 2011

Deciding whether to use cold remedies: Comment

Declarations of interest by members of Health Canada's special advisory committees and panels: a descriptive study

artículo científico publicado en 2019

Developing a Clinician Friendly Tool to Identify Useful Clinical Practice Guidelines: G-TRUST.

artículo científico publicado en 2017

Development Time and Patent Extension for Prescription Drugs in Canada: A Cohort Study

artículo científico publicado en 2020

Differences in the volume of pharmaceutical advertisements between print general medical journals

artículo científico publicado en 2014

Different conclusions about memantine

artículo científico publicado en 2007

Direct-to-consumer advertising of prescription medications: what the Canadian medical trainee needs to know

scientific article published on 24 July 2019

Disclosure at Pfizer Canada.

artículo científico publicado en 2002

Do higher drug costs lead to better health?

scientific article published on 07 January 2005

Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices

artículo científico publicado en 2006

Does an Orphan Drug Policy Make a Difference in Access? A Comparison of Canada and Australia

scientific article published on 06 November 2019

Does family medicine have a professional obligation to play a leading role in pharmaceutical industry-sponsored drug research?: no ⬇️

artículo científico publicado el 1 de agosto de 2011

Does the C in CME stand for "Continuing" or "Commercial"?

artículo científico publicado en 2005

Drug Promotion in India Since 2000: Problems Remain

artículo científico publicado en 2020

Drug advertising in medical journals

Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.

artículo científico publicado en 2017

Drug not considered a first-line agent

Drug prices: How do we get to a better place?

artículo científico publicado en 2017

Drug withdrawals from the Canadian market for safety reasons, 1963-2004.

artículo científico publicado en 2005

Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.

artículo científico publicado en 2003

Economics and industry do not mean ethical conduct in clinical trials

artículo científico publicado en 2013

Editorial

artículo científico publicado en 2018

Educating Health Professionals about Drug and Device Promotion: Authors' Reply

artículo científico publicado en 2007

Educating health professionals about drug and device promotion: advocates' recommendations

artículo científico publicado en 2006

Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence.

artículo científico publicado en 2004

Effects of restrictive formularies in the ambulatory care setting

artículo científico publicado en 2002

Enabling Patient Portals to Access Primary Care Medical Records: Maximizing Collaboration in Care between Patients and Providers

scientific article published on 01 May 2019

Financial Conflicts of Interest Checklist 2010 for clinical research studies

artículo científico publicado en 2010

Financial conflict of interest among clinical practice guideline-producing organisations

artículo científico publicado en 2020

Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study

artículo científico publicado en 2019

Financial costs associated with monopolies on biologic medicines in Australia

artículo científico publicado en 2017

Financial ties between leaders of influential US professional medical associations and industry: cross sectional study

artículo científico publicado en 2020

Foreign free riders and the high price of US medicines

artículo científico publicado en 2005

Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: a cohort study

artículo científico publicado en 2015

Gardasil® - The New HPV Vaccine: The Right Product, the Right Time? A Commentary ⬇️

artículo científico publicado el 1 de mayo de 2010

Harmony in Drug Regulation, but Who's Calling the Tune? An Examination of Regulatory Harmonization in Health Canada ⬇️

artículo científico publicado el 1 de enero de 2012

Healing an ailing pharmaceutical system: prescription for reform for United States and Canada

artículo científico publicado en 2018

Health Canada and the pharmaceutical industry: a preliminary analysis of the historical relationship

artículo científico publicado en 2013

Health Canada's Proposal to Accelerate New Drug Reviews

artículo científico publicado en 2020

Health Canada's Use of its Notice of Compliance With Conditions Drug Approval Policy: A Retrospective Cohort Analysis

artículo científico publicado en 2018

Health Canada's use of expedited review pathways and therapeutic innovation, 1995-2016: cross-sectional analysis

scientific article published on 30 August 2018

Health Canada's use of its priority review process for new drugs: a cohort study

artículo científico publicado en 2015

Hippocrates and Targin

artículo científico publicado en 2016

How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study

artículo científico publicado en 2016

How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA.

artículo científico publicado en 2003

How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study

artículo científico publicado en 2020

How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009

artículo científico publicado en 2014

How well do Canadian media outlets convey medical treatment information?: Initial findings from a year and a half of media monitoring by Media Doctor Canada ⬇️

artículo científico publicado el 22 de abril de 2008

Inaccessibility of drug reports

artículo científico publicado en 2002

Increase in Drug Spending in Canada Due to Extension of Data Protection for Biologics: A Descriptive Study

artículo científico publicado en 2019

Indicators for measuring mental health: towards better surveillance

artículo científico publicado en 2009

Industry sponsorship and research outcome

artículo científico publicado en 2012

Industry sponsorship and research outcome

artículo científico publicado en 2011

Industry sponsorship and research outcome.

artículo científico publicado en 2017

Industry sponsorship and research outcome: systematic review with meta-analysis

article

Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey

artículo científico publicado en 2002

Influenza vaccination of health care workers

artículo científico publicado en 2013

Information about a discontinued drug

artículo científico publicado en 2008

Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review

artículo científico publicado en 2010

Innovation and off-label use, the French case and more

scientific article published on 04 June 2019

Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs ⬇️

artículo científico publicado el 1 de enero de 2013

Institutional financial conflicts of interest policies at Canadian academic health science centres: a national survey.

artículo científico publicado en 2010

Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario

scientific article published on 24 July 2018

Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here?

artículo científico publicado en 2005

International comparison of assessments of pharmaceutical innovation ⬇️

artículo científico publicado el 8 de marzo de 2012

Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy

artículo científico publicado en 2005

Investigator experiences with financial conflicts of interest in clinical trials

artículo científico publicado en 2011

Is Australia's national medicines policy failing? The case of COX-2 inhibitors.

artículo científico publicado en 2007

Is there still a role for spontaneous reporting of adverse drug reactions?

artículo científico publicado en 2006

It's Time to Finally Kill the Zombies Comment on "Universal Pharmacare in Canada"

artículo científico publicado en 2020

Legislative regulation and ethical governance of medical research in different European Union countries ⬇️

artículo científico publicado el 10 de mayo de 2013

Longer Exclusivity Does Not Guarantee Better Drugs ⬇️

artículo científico publicado el 1 de abril de 2011

Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study

artículo científico publicado en 2017

Marketing before patenting: implications for price controls in Canada ⬇️

artículo científico publicado el 27 de julio de 2010

Marketing versus evidence-based medicine

artículo científico publicado en 2012

Medications for obesity.

artículo científico publicado en 2008

Medicine reimbursement recommendations in Canada, Australia, and Scotland.

artículo científico publicado en 2008

Medicines Information and the Regulation of the Promotion of Pharmaceuticals

artículo científico publicado en 2018

Medicines Save, Medicines Kill

artículo científico publicado en 2017

Models for financing the regulation of pharmaceutical promotion ⬇️

artículo científico publicado el 11 de julio de 2012

More than the diagnosis

artículo científico publicado en 2009

National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism

artículo científico publicado en 2019

National evaluation of policies on individual financial conflicts of interest in Canadian academic health science centers

artículo científico publicado en 2008

New CMA guide to drugs

artículo científico publicado en 1997

New CMAJ policy on competing interests in guidelines needs strengthening

artículo científico publicado en 2019

New directions in drug approval

artículo científico publicado en 2004

New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010?

artículo científico publicado en 2012

New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?

artículo científico publicado en 2002

Notice of Compliance with Conditions: A Policy in Limbo

artículo científico publicado en 2007

Notice of compliance with conditions: a policy in limbo

artículo científico publicado en 2007

Nursing Home Physicians Discuss Caring for Elderly Residents: An Exploratory Study

artículo científico publicado en 2018

Observational Evidence of For-Profit Delivery and Inferior Nursing Home Care: When Is There Enough Evidence for Policy Change?

artículo científico publicado en 2016

Of money and trust in biomedical care

artículo científico publicado en 2007

Of money and trust in medical care redux

artículo científico publicado en 2012

Off-Label Drug Use: Whose Interests Are Served?

artículo científico publicado en 2016

Off-label drug use and temporary recommendations for use: Rearranging the deckchairs on the Titanic?

artículo científico publicado en 2016

One step forward, one step sideways? Expanding research capacity for neglected diseases

artículo científico publicado en 2010

Opioid abuse ⬇️

artículo científico publicado el 19 de marzo de 2013

Patent law

artículo científico publicado en 2003

Pathways to independence: towards producing and using trustworthy evidence

scientific article published on 03 December 2019

Pharmaceutical Industry-Initiated Postapproval Studies-Not Requested by the US FDA, Little Value, and Many Questions

scientific article published on 03 May 2019

Pharmaceutical Sales Representatives and Patient Safety: A Comparative Prospective Study of Information Quality in Canada, France and the United States ⬇️

artículo científico publicado el 5 de abril de 2013

Pharmaceutical company advertising in The Lancet

scientific article published on 01 July 2011

Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis.

artículo científico publicado en 2018

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

artículo científico publicado en 2003

Pharmaceutical innovation: can we live forever? A commentary on Schnittker and Karandinos

artículo científico publicado en 2010

Pharmaceutical sales representatives and patient safety

artículo científico publicado en 2013

Pharmacovigilance in Europe and North America: Divergent approaches ⬇️

artículo científico publicado el 3 de abril de 2012

Physician awareness of diagnostic and nondrug therapeutic costs: a systematic review

artículo científico publicado en 2008

Physician awareness of drug cost: a systematic review

artículo científico publicado en 2007

Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews ⬇️

artículo científico publicado el 9 de marzo de 2013

Poor reporting of scientific leadership information in clinical trial registers.

artículo científico publicado en 2008

Post-market safety communication for protection of public health: a comparison of regulatory policy in Australia, Canada, the European Union, and the United States

artículo científico publicado en 2020

Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy

artículo científico publicado en 2015

Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study

artículo científico publicado en 2014

Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study

artículo científico publicado en 2015

Prescribing errors

artículo científico publicado en 2005

Prescription drug safety

artículo científico publicado en 1993

Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary

artículo científico publicado en 2009

Priority reviews: innovation and safety

artículo científico publicado en 2017

Progressive licensing of drugs: music or noise?

artículo científico publicado en 2008

Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agencies

artículo científico publicado en 2009

Provincial Drug Plan Officials' Views of the Canadian Drug Safety System ⬇️

artículo científico publicado el 15 de febrero de 2013

Publication of confirmatory studies required by Health Canada for drugs approved under a Notice of Compliance with conditions: a cohort study.

artículo científico publicado en 2017

Qualitative research and the politics of knowledge in an age of evidence: developing a research-based practice of immanent critique

artículo científico publicado en 2008

Quality and quantity of information in summary basis of decision documents issued by health Canada

artículo científico publicado en 2014

Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study

artículo científico publicado en 2020

Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study

artículo científico publicado en 2018

Questions about Adderall XR.

artículo científico publicado en 2006

Rebuttal

artículo científico publicado en 1997

Rebuttal: Does family medicine have a professional obligation to play a leading role in pharmaceutical industry–sponsored drug research?: NO

Rebuttal: are drugs too expensive in Canada?

artículo científico publicado en 2006

Reconciling a "pleasant exchange" with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care

artículo científico publicado en 2018

Reforms to the patented medicine prices review board and the introduction of new drugs in Canada: An observational study

artículo científico publicado en 2022

Regulating Information or Allowing Deception? Pharmaceutical Sales Visits in Canada, France, and the United States.

artículo científico publicado en 2016

Regulating drugs for effectiveness and safety: a public health perspective

artículo científico publicado en 2007

Regulating prescription drugs for patient safety: does Bill C-17 go far enough?

artículo científico publicado en 2014

Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19

artículo científico publicado en 2021

Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study

artículo científico publicado en 2006

Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study

artículo científico publicado en 2012

Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments

artículo científico publicado en 2011

Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study

artículo científico publicado en 2020

Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study

artículo científico publicado en 2020

Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase

artículo científico publicado en 2016

Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009

artículo científico publicado en 2020

Response

Restoring the Bacloville trial: efficacy and harms

artículo científico publicado en 2020

Réfutation : La médecine familiale a-t-elle une obligation professionnelle de jouer un rôle prépondérant dans la recherche sur les médicaments financée par l’industrie pharmaceutique?: NON

Safeguarding the Quality of Clinical Research ⬇️

artículo científico publicado el 1 de julio de 2003

Secret safety warnings on medicines: A case study of information access requests

scientific article published on 06 March 2019

Should the C in CME Stand for Commercial? ⬇️

artículo científico publicado el 1 de julio de 2012

Six Myths About Pharmacare

artículo científico publicado en 2017

Skilled use of the media by vested interests to promote drugs and other health products

artículo científico publicado en 2016

Sponsorship bias in clinical research

artículo científico publicado en 2012

Statistics can affect treatment decisions

artículo científico publicado en 2003

Stop the merry-go-round

scientific article published on 01 January 2004

Summary Basis of Decision in context.

artículo científico publicado en 2005

Surrogate outcomes in clinical trials: a cautionary tale

artículo científico publicado en 2013

Ten Principles for More Conservative, Care-Full Diagnosis

The "Nuts and Bolts" of Opioid Marketing: Promotional Messages to Family Doctors in Sacramento, Vancouver, Montreal, and Toulouse

scientific article published on 10 February 2020

The "pharmaceuticalisation" of life

artículo científico publicado en 2019

The FDA's new clothes

artículo científico publicado en 2015

The Pharmaceutical Industry and the Canadian Government: Folie à Deux

artículo científico publicado en 2017

The Rise and Fall of the Neurotic Housewife: Patient Sex in Psychotropic Drug Advertising to Physicians 1946-1990

artículo científico publicado en 2020

The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia

artículo científico publicado en 2016

The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries

artículo científico publicado en 2017

The association between a journal's source of revenue and the drug recommendations made in the articles it publishes

artículo científico publicado en 2011

The cost of drug development: A systematic review ⬇️

artículo científico publicado el 21 de enero de 2011

The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States

artículo científico publicado en 2008

The danger of imperfect regulation: OxyContin use in the United States and Canada ⬇️

artículo científico publicado el 1 de enero de 2011

The effect of early in-hospital medication review on health outcomes: a systematic review

artículo científico publicado en 2015

The effect of generic competition on the price of brand-name drugs

artículo científico publicado en 2004

The pharmaceutical industry as a medicines provider

artículo científico publicado en 2002

The relation between promotional spending on drugs and their therapeutic gain: a cohort analysis

artículo científico publicado en 2017

The secret things belong unto the Lord our God: secrecy in the pharmaceutical arena.

artículo científico publicado en 2007

The siren call of new drugs

artículo científico publicado en 2003

Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications ⬇️

artículo científico publicado el 15 de febrero de 2011

Too few, too weak: conflict of interest policies at Canadian medical schools

artículo científico publicado en 2013

Too much disclosure of product risks? CBC television, SOGC, and Diane-35.

artículo científico publicado en 2003

Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence

scientific article published on 22 August 2018

Transparency in drug regulation: mirage or oasis?

artículo científico publicado en 2004

Treating hyperkalaemia

artículo científico publicado en 2003

Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?

artículo científico publicado en 2017

Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature

scientific article published on 24 December 2019

Voluntary Self-Regulatory Codes: What Should We Expect? ⬇️

artículo científico publicado el 1 de enero de 2003

We need to mandate drug cost transparency on electronic medical records

artículo científico publicado en 2017

What do Canadians think about physician-pharmaceutical industry interactions?

artículo científico publicado en 2013

Who assigns value in value-based insurance design?

artículo científico publicado en 2020

Who should fund CME? ⬇️

artículo científico publicado el 1 de mayo de 2013

Why are there deadly drugs?

artículo científico publicado en 2015

Why do cancer drugs get such an easy ride?

artículo científico publicado en 2015

Will Lower Drug Prices Jeopardize Drug Research? A Policy Fact Sheet

journal article; published in The American Journal of Bioethics in 2004

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda